Arcus Biosciences, Inc.

191 articles about Arcus Biosciences, Inc.

• Arcus Biosciences Announces Pricing of Initial Public Offering

  3/14/2018

  Arcus Biosciences announced the pricing of its initial public offering of 8,000,000 shares of common stock at a price to the public of $15.00 per share for total gross proceeds of $120,000,000.

• Arcus Biosciences Appoints David Beier to Board of Directors

  12/18/2017

  Mr. Beier brings extensive experience in the biopharmaceutical industry, particularly in areas such as healthcare policy, government affairs, regulatory affairs, pricing, healthcare economics and product commercialization.

• 

  Sage Therapeutics Fills Its Pockets

  11/27/2017

  Sage Therapeutics has been on a roll with good news lately.
• 

  Bay Area's Arcus Biosciences Scores $107M, Initiates Two Clinical Trials

  11/13/2017

  Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing.

• Bay Area Startup Arcus Biosciences Lands $307 Million+ Deal With Taiho Pharma

  9/21/2017

• Arcus Biosciences Appoints Kate Falberg To Its Board Of Directors

  9/18/2017

• Arcus Biosciences, Wuxi Biologics Hammer Out R&D Cancer Pact Worth $816 Million+

  8/17/2017

• What You Need to Know About Arcus Biosciences

  1/12/2017

• 

  The Next Generation: Top 20 Life Science Startups to Watch in 2017

  1/9/2017

  BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.

• Taiho Ventures Invests In Arcus Biosciences As Part Of $70 Million Series B Investment Round

  9/2/2016

• Bay Area Startup Arcus Biosciences Emerges With $120 Million

  8/30/2016